Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
1954
16.2K+
LTM Revenue n/a
LTM EBITDA n/a
$28.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Coloplast has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Coloplast achieved revenue of $3.8B and an EBITDA of $1.2B.
Coloplast expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Coloplast valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $3.2B | $3.4B | $3.8B | n/a | XXX |
Gross Profit | $2.2B | $2.3B | $2.6B | XXX | XXX |
Gross Margin | 69% | 67% | 68% | XXX | XXX |
EBITDA | $1.0B | $1.1B | $1.2B | n/a | XXX |
EBITDA Margin | 32% | 32% | 31% | NaN% | XXX |
Net Profit | $657M | $668M | $706M | XXX | XXX |
Net Margin | 21% | 20% | 19% | XXX | XXX |
Net Debt | $2.5B | $2.5B | $2.9B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Coloplast's stock price is DKK 786 (or $110).
Coloplast has current market cap of DKK 177B (or $24.8B), and EV of DKK 201B (or $28.1B).
See Coloplast trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$28.1B | $24.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Coloplast has market cap of $24.8B and EV of $28.1B.
Coloplast's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Coloplast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Coloplast and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $28.1B | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpColoplast's NTM/LTM revenue growth is n/a
Coloplast's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Coloplast's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Coloplast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Coloplast and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 10% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 10% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
Opex to Revenue | 41% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coloplast acquired XXX companies to date.
Last acquisition by Coloplast was XXXXXXXX, XXXXX XXXXX XXXXXX . Coloplast acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Coloplast founded? | Coloplast was founded in 1954. |
Where is Coloplast headquartered? | Coloplast is headquartered in Denmark. |
How many employees does Coloplast have? | As of today, Coloplast has 16.2K+ employees. |
Who is the CEO of Coloplast? | Coloplast's CEO is Mr. Kristian Villumsen. |
Is Coloplast publicy listed? | Yes, Coloplast is a public company listed on CSE. |
What is the stock symbol of Coloplast? | Coloplast trades under COLO B ticker. |
When did Coloplast go public? | Coloplast went public in 1993. |
Who are competitors of Coloplast? | Similar companies to Coloplast include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
What is the current market cap of Coloplast? | Coloplast's current market cap is $24.8B |
What is the current revenue growth of Coloplast? | Coloplast revenue growth between 2023 and 2024 was 10%. |
Is Coloplast profitable? | Yes, Coloplast is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.